Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

Associations between ethnicity, social contact, and pneumococcal carriage three years post-PCV10 in Fiji

Indigenous iTaukei had greater frequency and intensity of contact compared with Fijians of Indian Descent

Research

The Use of Test-negative Controls to Monitor Vaccine Effectiveness: A Systematic Review of Methodology

Our review highlights similarities and differences in the application of the test-negative design that deserve further examination

Research

S. aureus colonization in healthy Australian adults receiving an investigational S. aureus 3-antigen vaccine

Based on descriptive analyses of this small study, S. aureus 3-antigen vaccine vaccination did not impact S. aureus acquisition or carriage

Research

Safety and immunogenicity of a vero cell culture-derived whole-virus influenza a(H5N1) vaccine in a pediatric population

This study examined the safety and immunogenicity of a vero cell culture-derived whole-virus influenza a(H5N1) vaccine in a pediatric population.

Research

Position statement of the World Heart Federation on the prevention and control of rheumatic heart disease

In the 21st century, rheumatic fever (RF) and rheumatic heart disease (RHD) are neglected diseases of marginalized communities.

Research

Safety and tolerability of a 2009 trivalent inactivated split-virion influenza vaccine in infants, children and adolescents

To evaluate the safety of CSL's split-virion inactivated trivalent 2009 Southern Hemisphere formulation influenza vaccine (TIV) in children.

Research

TLR3 and RIG-I gene variants: Associations with functional effects on receptor expression and responses to measles viru

Measles virus causes severe morbidity and mortality, despite the availability of measles vaccines. Successful defence against viral pathogens requires early...

Research

Predominance of nontypeable haemophilus influenzae in children with otitis media

In Australia the 7-valent pneumococcal conjugate vaccine (PCV7) is administered at 2, 4 and 6 months of age, with no booster dose.

Research

Pneumococcal conjugate vaccination at birth in a high-risk setting: No evidence for neonatal T-cell tolerance

Concerns about the risk of inducing immune deviation-associated "neonatal tolerance" as described in mice have restricted the widespread adoption...

Research

Slam and dc-sign measles receptor polymorphisms and their impact on antibody and cytokine responses to measles vaccine

Despite the use of measles vaccine, measles virus continues to circulate and cause severe disease